IB Net Payout Yields Model

Invest like me - only at Covestor.com

Synergy Pharma: Important Numbers

By -
Synergy Pharma continues to grow extended prescription units for Trulance.
Competitor drug Linzess produced a highly profitable Q4.
Trulance prescription growth appears to lag the revenue estimates, especially in Q1.
With financing in place and a spring ramp in prescriptions, the stock is positioned for buying any weakness related to missing revenue targets.
With all of the drama surrounding executive leadership and cash burn at Synergy Pharma (SGYP), the market hasn't focused as much on the prescription data of Trulance. The stock has held close to $2 suggesting healthy investor appetite for the biotech at this level, but meeting 2018 targets could create further weakness in Synergy Pharma providing an opportunity to own the stock at lower prices.
Read the full article on Seeking Alpha. 

Disclosure: Long SGYP. Please review the disclaimer page for more details. 


Comments

imlanguages said…
Very well written article. It was awesome article to read. pricepropharmacy.com gives you Linzess at normal price. It’s a great pleasure reading your post. It’s useful information.
October 21, 2020 at 4:54 AM
90-Day Meds said…
It is a valuable blog that you have shared here. You are a well-informed author, I got some knowledge and henceforth, I should thank you for the undertakings you have made in this article. spiriva prescription cost
December 12, 2020 at 12:39 AM
90-Day Meds said…
It's a nice article, Which you have shared here about the pharmacy. Your article is very informative and I really liked the way you expressed your views in this post. Thank you.https://www.90daymeds.com/product/lantus-solostar/
February 16, 2021 at 8:55 AM
PricePro Pharmacy said…
Enjoyed reading this article; in fact, everything is explained in detail, the article is fascinating and compelling. Order Affordable Canadian Pharmacy Bystolic online by visiting our website.
February 16, 2021 at 4:43 PM
Garner Supply said…
Great information! If you are looking for information on medical devices and how to use them efficiently to live their best lives, you can check https://www.garnersupply.com/articles/
April 9, 2021 at 9:42 AM
continuumindia said…
Excellent job, this is great information which is shared by you. This info is meaningful and factual for us to increase our knowledge about it. So please always keep sharing this type of information. Read more info about complete pharmacovigilance solutions
October 16, 2021 at 6:42 PM
Buypillsandsteroidsonline said…
Excellent knowledge, You are providing important knowledge. It is really helpful and factual information for us and everyone to increase knowledge. Continue sharing your data. Thank you. Read more info about Buy Authentic Post Cycle Therapy Steroid USA
February 2, 2022 at 5:50 PM
Post a Comment

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts struggle to make the bullish case on expen
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more